BioSpace News Archive

Exactus, Inc. (OTCQB:EXDI) (the “Company”), a hemp farmer and manufacturer of hemp-derived phytocannabinoid products, today announced new initiatives to expand its sales, marketing and distribution by establishing new e-commerce platforms with the addition of experienced professionals responsible for building out its wholesale, retail and direct to consumer sales channels.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule, Inc. (Nasdaq: ARQL). On Dec. 9, 2019

Study finds PEKK displayed potential advantages to bone growth characteristics when compared to PEEK and Titanium-coated PEEK in an ovine bone defect model

Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to treat CLI

The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected Alistair Macdonald, Chief Executive Officer of Syneos Health, as 2020 Chair.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that the Company is nearing completion of the second production cycle, of recombinant spider silk, at its Vietnamese production factory.

Seer, Inc., a life sciences company focused on capturing and translating proteome insights to advance human health, today announced it has raised $55 million in an oversubscribed Series D equity financing.

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer.

Successful impregnation of gum arabic-CoQ10 bolsters Ceapro’s efforts to develop innovative delivery systems composed of new chemical complexes

Dr Arif Anwar will present an overview of the commercialisation strategy of the company, as well as applications of its well-differentiated and patented KREX™ technology for intra-disease stratification and autoimmune and cancer immunotherapy drug response prediction.